Earnings Call for Q2FY22 of SMS Pharmaceuticals
Conference Call with SMS Pharmaceuticals Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transcript.17-11-2021
17-11-2021
SMS PHARMACEUTICALS LTD. - 532815 - Revised Intimation Of Conference Call Ref: Regulation 30(6) Of SEBI (LODR) Regulations, 2015
This is to inform you that Conference Call for the Investors and Analysts has been scheduled on Wednesday, November 17, 2021 at 11:00 AM IST to discuss the Company's financial performance for the Quarter and half year ended September 30, 2021. Please find attached herewith invitation for the same. Kindly take the same on record.16-11-2021
SMS Pharmaceuticals Ltd - 532815 - Intimation Of Conference Call Ref: Regulation 30(6) Of SEBI (LODR) Regulations, 2015
This is to inform you that Conference Call for the Investors and Analysts has been scheduled on Wednesday, November 16, 2021 at 11:00 AM IST to discuss the Company's financial performance for the Quarter and half year ended September 30, 2021. Please find attached herewith invitation for the same. Kindly take the same on record.16-11-2021
SMS PHARMACEUTICALS LTD. - 532815 - Intimation Of Conference Call Ref: Regulation 30(6) Of SEBI (LODR) Regulations, 2015
This is to inform you that Conference Call for the Investors and Analysts has been scheduled on Wednesday, November 17, 2021 at 11:00 AM IST to discuss the Company's financial performance for the Quarter and half year ended September 30, 2021. Please find attached herewith invitation for the same. Kindly take the same on record.16-11-2021
Q2FY22 Quarterly Result Announced for SMS Pharmaceuticals Ltd.
Highlights: Revenue grew by 34% YoY EBITDA Margin expanded by 867bps to 27.6%, driven by improved product mix and realisations Profit after tax (PAT) grew by 123% YoY Commenting on the results Mr. P. Vamsi Krishna, Executive Director - SMS Pharmaceuticals Limited said, "The company continued to maintain the robust growth trajectory. For Q2FY22, thecompany registered revenue, EBITDA and PAT growth of 34%, 96% and 123%, respectively, on YoY basis. EBITDA margins expanded approximately by 870bps. The robust performance was driven by improved product mix, pick-up in the key therapeutic areas and the operating leverage. This performance a testimony of company's agility, adaptability and strong execution capabilities. The growth trajectory is expected to accelerate in the upcoming quarters underpinned by company's leadership position in top therapeutic areas, strong demand, healthy product launch pipeline. SMS Pharma, as a strategy, has focused on quality, market leadership and backward integration steered by strong R&D; capabilities, in top therapeutic areas such as ARV, anti-migraine and anti ulcer over the years. This strategy has boded well, as the company did not witness any impact by recent supply chain disruptions and higher input costs. It has also reduced the import dependency on China significantly for KSMS and key raw materials. Company's global presence, strong domain expertise, cost leadership, economies of scale and long standing relationships with suppliers and customers has created a unique value proposition. As a result, SMS Pharma has emerged as sustainable, scalable and self-reliant API player. Going forward, the company will continue to invest in backward integration to further strengthen the value proposition. The company is also leveraging long-standing relationships and domain expertise to foray into new therapies, products and geographies. The company has incurred a capex of Rs. 198 crores in FY21 aimed towards capacity augmentation at the Vizag plant. This brownfield capex is aimed towards capacity augmentation multiple products and therapies. The incremental capacity addition through the capex is 1,300 KL, predominantly aimed towards Ibuprofen capacity expansion. With this capex, company is expected to be one of the largest Ibuprofen manufacturers globally. Majority of the capex is funded through internal accruals and minimal debt, thus maintaining the robust Balance Sheet position. Higher margins and profitability ratios expected through operating leverage and incremental revenue. This capacity augmentation is expected to commercialize fully by the end of FY22. Multiple industry tailwinds such as favourable geo-political conditions, Make in India, PLI Scheme, China+1 strategy, cost structure coupled with internal triggers such as capacity expansion, leadership position in key therapies and strong balance sheet are expected to drive the next leg of growth along with improved margins and return ratios." Result PDF15-11-2021
SMS Pharmaceuticals Ltd - 532815 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Further to our intimation dated November 12, 202 1. Please find enclosed herewith copies of the newspaper advertisements published in Financial Express and Andhra Prabha on November 14, 2021, regarding financial results for quarter and half yearly ended September 30, 202 1. Please note that this information is published within 4B hours of closure of the Board meeting as specified in Regulation 47(3) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.15-11-2021
SMS PHARMACEUTICALS LTD. - 532815 - Press Release
Please find attached the press release on the Financial Results for the quarter ended 30th September,2021.13-11-2021
SMS PHARMACEUTICALS LTD. - 532815 - Announcement under Regulation 30 (LODR)-Investor Presentation
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed a herewith a copy of investor presentation of the Company. This Investor Presentation may also be accessed on the website of the Company at www.smspharma.com13-11-2021
SMS Pharmaceuticals Ltd - 532815 - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
With reference to the captioned subject and in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Mr.V S.Venkatish (M.No: A-21785) has tendered resignation from the post of Company Secretary & Compliance officer of the Company. The Company has accepted his resignation and he will be relived him from responsibilities on or before 31st January, 2022. We request you to please take the same on Record12-11-2021
SMS Pharmaceuticals Ltd - 532815 - Outcome Of Board Meeting Held On 12Th November, 2021
With reference to the above subject, we would like to inform you that Board of Directors of the Company at their meeting held today, inter-alia considered and approved the following: 1. The Standalone and Consolidated Un-audited Financial Results for the Quarter and half year ended 30th September, 2021 along with the Limited Review Report. 2. Approved the resignation of Mr. V S Venkatish, Company Secretary and Compliance Officer, and he will be relieved on or before 31st January, 2022.12-11-2021